Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma

摘要: Purpose The aim of the current study is to compare clear cell ovarian carcinoma (CCOC) and papillary serous (PSOC) with respect their clinical features expression different regulators cycle, apoptosis, chemoresistance. Experimental Design Women stage III CCOC (n = 9) those III, poorly differentiated PSOC (n = 21) seen between 1996 2000 treated cytoreductive surgery followed by paclitaxel platinum chemotherapy were compared in demographic features, tumor marker profile, surgical substage, results surgery, thromboembolic complications, response chemotherapy, recurrence. Tumor samples p53, Bcl2, Bclx, Bax, p21, p-glycoprotein (PGP), multi-drug resistance-associated protein (MRP), lung resistance (LRP), glutathione S-transferase (GST) using immunohistochemistry. Results Women had significantly lower mean preoperative CA-125 values, less more p21 than women (P = 0.037, 0.012, 0.008, 0.009, respectively). Women ascites, smaller amount residual tumor, higher incidence thromboembolism, chemoresistance, PGP (P = 0.067, 0.078, 0.108, 0.114, 0.091, 0.118, respectively). Conclusions Women exhibit certain molecular differences stage- grade-matched PSOC. have a volume manifest expressions Bcl2 Although further studies larger number patients are needed, our findings indicate that chemoresisatnce probably not p53-dependent. J. Surg. Oncol. 2006;93:379–386. © 2006 Wiley-Liss, Inc.